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NEWBORN SCREENING PROGRAMS AND PRIVACY: 
SHIFTING RESPONSffiILITY FROM THE PARENT TO THE 
LABORATORY 
1. INTRODUCTION 
Imagine a parent takes her one-month-old child for a checkup only 
to be told by the pediatrician that the child carries a certain gene 
indicative of cystic fibrosis. 1 The parent wonders how the 
pediatrician knows this information since the pediatrician never took 
a blood sample from the infant. 2 The pediatrician explains that all 
newborns are screened at birth for a panel of genetic diseases as is 
mandated by the government.3 In many cases, however, this testing 
is done without proper informed consent of the parents, who are 
unaware that a DNA sample is being taken.4 The above story is true 
and resulted in multiple lawsuits in several different states claiming 
that the infant's privacy was violated.5 
These cases resulted in reform regarding consent to newborn 
screenings,6 but problems still remain. The major problem facing 
newborn screening programs is the fact that technology has 
progressed tremendously since the inception of such programs. 7 
Newborn screening began in the 1960s and tested only a small 
number of diseases.8 Since then, technology has developed to the 
point where we cannot only test infants for a multitude of diseases, 
but we can sequence an entire genome and are on a path to 
determining the personality traits as well as physical traits of the 
1. Elizabeth Cohen, The Government Has Your Baby's DNA, CNN (Feb. 4, 2010), 




5. Id.; see, e.g., Higgins v. Tex. Dep't of Health Servs., 801 F. Supp. 2d 541,544,546 
(W.D. Tex. 2011); Bearderv. State, 806 N.W.2d 766, 769 (Minn. 2011). 
6. See Dena S. Davis, Opportunistic Testing: The Death of Informed Consent? 23 
HEALTH MATRIX 35, 42 (2013); Rachel L. Schweers, Comment, Newborn Screening 
Programs: How Do We Best Protect Privacy Rights While Ensuring Optimal 
Newborn Health?, 61 DEPAULL. REv. 869,909 (2012). 
7. See Davis, supra note 6, 42. 
8. Id. at 41-42. 
105 
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patient. 9 This progression in technology raises many privacy-rights 
issues, not the least of which is that the essence of a person is in 
danger of being inappropriately accessed or disseminated. 10 
The solution is to, first and foremost, fundamentally change the 
way we view genetic information and move from our outdated way 
of thinking to a more modem way of thinking that is aware of the 
dangers new technology may pose. To do this, this Cornment 
proposes that we implement a two-pronged approach. II First, 
legislation should require parental informed consent in order for the 
infant to participate in the newborn screening program. 12 Second, 
legislation should place the onus on healthcare providers, 
corporations, research institutions, and other entities not to violate the 
parents' or infant's privacy rights. 13 This would effectively shift the 
burden away from the parent and would not put the infant's genetic 
information at risk. 14 Additionally, new legislation must be 
implemented that would focus specifically on encompassing and 
protecting all genetic information, no matter its form or method of 
sampling. 15 
In Part II, this Comment will give an overview of the history of 
genetic testing as well as history specific to newborn screenings, 
induding current and potential future technologies. 16 The following 
section will discuss positive aspects of newborn screenings as well as 
the current newborn screening process and current legislation and 
governmental policies relating to newborn screening programs. 17 In 
Part IV, this Comment will discuss negative implications associated 
with current newborn screening programs in the United States. 18 In 
that same section, this Comment will discuss different theories as to 
how to solve the problems created by current newborn screening 
9. Frequently Asked Questions About Genetic Testing, NAT'L HUMAN GENOME 
RESEARCH INST., http://www.genome.gov/19516567#al-5 (last updated Mar. 11, 
2014). 
10. See Cohen, supra note 1; see also Stefan Timmennans, Genetic Screening: Every 
Newborn a Patient, Los ANGELES TIMES (July 19, 2013), 
http://articles.latimes.coml2013/juIl19/opinionlla-oe-timmennans-infant-genetic-
screening-20 130719 (discussing the hann parents suffer from false positive results). 
11. See infra Part IV-V. 
12. See infra Part IV. 
13. See infra Part V. 
14. See infra Part V. 
15. See, e.g., Health Information Privacy, U.S. DEP'T OF HEALTH & HUMAN SERVS., 
http://www.hhs.gov/ocr/privacy/(last visited Nov. 17,2014). 
16. See infra Part II. 
17. See infra Part III. 
18. See infra Part IV. 
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programs. 19 Finally, Part V of this Comment will set forth an 
overview of legislative guidelines which would solve many of the 
problems facing newborn screening programs. 20 
II. OVERVIEW OF GENETIC TESTING AND HISTORY OF 
NEWBORN GENETIC SCREENINGS 
A. Genetic Testing Overview 
Genetic tests use drawn blood and other tissue to determine if an 
individual carries certain genetic disorders.21 To do this, the drawn 
blood is analyzed to determine if any changes in chromosomes, 
genes, or proteins exist,22 and "[t]he results of a genetic test can 
confirm or rule out a suspected genetic condition or help determine a 
person's chance of developing or passing on a genetic disorder."23 
There are several different methods used to test the patient's blood 
sample.24 
First, "molecular genetic tests" analyze "single genes . . . to 
identify variations or mutations that lead to a genetic disorder."25 
Second, "chromosomal genetic tests" examine entire "chromosomes . 
. . to see if there are large genetic changes, such as an extra copy of a 
chromosome, that cause a genetic condition. "26 Third, "biochemical 
genetic tests" look at "the amount or activity level of proteins; 
abnormalities in either can indicate changes to the DNA that result in 
a genetic disorder."27 Additionally, testing can be done using direct-
to-consumer (DTC) testing kits.28 These kits allow the consumer to 
test for certain diseases in their own home.29 These DTC tests can 
19. See infra Part IV. 
20. See infra Part V. 
21. Genetic Testing, MEDLINEPLUS, http;llwww.nlm.nih.gov/medlineplus/genetictesting.html 
(last updated July 11,2014). The sample analyzes the deoxyribonucleic acid (DNA) 
in the patient's tissue to obtain the results. Tests and Procedures: Genetic Testing, 
MAYO CLINIC (July 19, 2013), http;llwww.mayoclinic.orgitests-procedures/genetic-
testinglbasics/definitionIPRC-200 14802. 






27. Id. Generally, newborn screenings use the biochemical test technique to determine 
the existence of genetic conditions in the baby's DNA. Frequently Asked Questions 
About Genetic Testing, supra note 9. 
28. Frequently Asked Questions About Genetic Testing, supra note 9. 
29. See id. 
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identify changes in some or all of an individual's genome to detect 
the risk of developing particular diseases, to help develop a 
personalized nutrition plan, or to detect genetic markers that indicate 
an individual's physical traits, ancestry, or personality.30 For adults, 
this testing is voluntary. 31 
In 2003, researchers at the Human Genome Research Institute 
completed their goal of mapping and sequencing the entire human 
genome.32 Human genome "[s]equencing involves determining the 
order of the chemical units of DNA" and "helps determine inherited 
traits, like susceptibility to some diseases."33 Once the sequence is 
known, scientists can then determine "the kind of genetic information 
that is carried in a particular segment of DNA."34 The sequencing of 
the genome has given researchers a "virtual blueprint of the human 
being," and future research will attempt to make sense of that 
"blueprint."35 Additionally, sequencing the human genome is 
30. ld. 
31. Ariel Bleicher, Perils of Newborn Screening, 307 SCI. AM. 30,30 (July I, 2012), 
available at http://www.scientificamerican.comlartic1e/perils-of-newbom-screening!. 
32. All About the Human Genome Project (HGP), NAT'L HUMAN GENOME RESEARCH 
INST., http://www.genome.gov/IOOOI772(lastupdatedMar.18.2014).This gave 
researchers the ability "to read nature's complete genetic blueprint for building a 
human being." ld. 
33. Andrew Pollack, Company Unveils DNA Sequencing Device Meant to be Portable. 
Disposable and Cheap, N.Y. TIMES (Feb. 17, 2012), 
http://www.nytimes.coml20 12/02/18lhealthloxford-nanopore-unveils-tiny-dna-
sequencing-device.html. 
All genes are made up of stretches of these four bases, arranged in 
different ways and in different lengths. HGP [Human Genome 
Project] researchers have deciphered the human genome in three 
major ways: determining the order, or "sequence," of all the bases 
in our genome's DNA; making maps that show the locations of 
genes for major sections of all our chromosomes; and producing 
what are called linkage maps . . . through which inherited traits 
(such as those for genetic disease) can be tracked over 
generations. 
An Overview of the Human Genome Project, NAT'L HUMAN GENOME RESEARCH INST., 
http://www.genome.gov/12011238 (last reviewed Nov. 8,2012). 
34. DNA Sequencing, NAT'L HUMAN GENOME REsEARCH lNST., http://www.genome.gov/lOOOI177 
(last reviewed Dec. 27, 2011). 
35. See id. 
However, this accomplishment should be viewed not as an end in 
itself, but rather as a starting point for even more exciting 
research. Armed with the human genome sequence, researchers 
are now trying to unravel some of biology's most complicated 
processes: how a baby develops from a single cell, how genes 
coordinate the functions of tissues and organs, how disease 
predisposition occurs and how the human brain works. 
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expensive, but the National Human Genome Research Institute is in 
the process of lowering the cost of sequencing the genome to a more 
reasonable price.36 
B. Newborn Screening History 
Newborn screening began in the 1960s as techniques were 
developed to determine whether an infant was affected by 
Phenylketonuria (PKU).37 In 1975,90% of newborns were tested for 
PKU.38 Soon thereafter, states began implementing similar tests to 
determine the probability of contracting other diseases for which 
treatments are available.39 Currently, all states require newborn 
screening for markers of medical disorders.40 
In the 1990s, the tandem mass spectrometry tool enabled 
technicians to detect more disorders using only a single drop of 
blood41 and significantly increased the number of diseases tested by 
the screening pane1.42 Further, "research has indicated that [mass 
spectrometry] has a false positive rate up to ten-fold lower for PKU 
screening than the best method previously available;" this makes it 
extremely effective.43 In addition, genome-sequencing technologies 
will eventually become inexpensive enough that they can be used 
routinely and thereby cause another rapid expansion for newborn 
screenings.44 To this point, a British company recently announced 
the sale of a disposable gene-sequencing device that can plug into a 
Id. 
36. Davis, supra note 6, at 42. 
37. Schweers, supra note 6, at 875. PKU is "a rare genetic disorder that can cause mental 
retardation but is treatable by diet modifications if detected early." Id. 
38. Id. 
39. Bleicher, supra note 31. Some of these diseases "includ[ ed] congenital 
hypothyroidism and sickle cell disease." Id. 
40. Id. 
41. Id. "A mass spectrometer sorts and counts [variously] sized molecules in the blood, 
somewhat like a change machine sorts coins. Unusually high levels of certain 
molecules indicate the enzymes that normally break down these molecules are 
missing or deficient, which in tum suggests a genetic disorder." Id. 
42. Lauren E. Fisher, Comment, The Use of Tandem Mass Spectrometry in Newborn 
Screening: Australia's Experience and Its Implications for United States Policy, 15 
PAC. RIM L. &POL'y J. 137, 145 (2006). 
43. Id. at 147. 
44. Bleicher, supra note 31 (citing Lainie Friedman Ross, an ethicist and pediatrician at 
the University of Chicago). Ross also says "there is the potential to test for hundreds 
of conditions we don't fully understand." Id. 
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computer to deliver its results; all for a price of $900.45 The private 
sector currently uses an even more effective way to test a patient's 
blood and sequence their genome.46 This new technology uses a 
microchip to "screen directly for the genetic basis of various 
disorders."47 
III. NEWBORN SCREENING PROCESS AND LEGISLATION 
A. Newborn Screening Process 
Typically, a blood test is performed 24 to 48 hours after the baby is 
born.48 To collect a blood sample, the baby's heel is pricked to obtain 
several drops of blood.49 This blood is then placed on a piece of 
special paper and sent for laboratory analysis. 50 If there are 
abnonnalities, "additional testing is required to confirm the [first 
test's] result."51 Moreover, "[d]ifferent labs have different 
procedures for notifying families and pediatricians of the results."52 
Sometimes the results are sent to the hospital where the child was 
born; sometimes they are sent directly to the doctor. 53 Once the 
results are determined, laboratories keep the samples as part of a 
databank in accordance with the laws of the state in which the sample 
was taken. 54 
B. Newborn Screening Program Policies and Legislation 
Currently, "newborn screening varies from state to state."55 Some 
states test for more than twenty-nine different conditions, while other 
states test for fewer than fifteen conditions.56 As technology has 
45. Pollack, supra note 33. This is not the only attempt at a portable, inexpensive 
sequencing device (though this seems to be the most successful as of yet). See id. 
46. See Davis, supra note 6, at 41-42. 
47. Id. at 42. 




52. Newborn Screening Tests, KIDsliEALTH, 
http://kidshealth.orgiparent/system/medical/newbom_screeninK-tests.html (last visited June 
27,2014). 
53. Id. 
54. See Davis, supra note 6, at 47-48. 
55. Newborn Screening, supra note 48. There are programs in all 50 states and the 
District of Columbia. Schweers, supra note 6, at 879. 
56. See Schweers, supra note 6, at 879 n.48. For a full list of conditions screened for by 
state, see Conditions Screened by State, BABY'S FIRST TEST, 
http://www.babysfirsttest.orglnewbom-screeninglstates (last visited Nov. 17,2014). 
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improved, it has become easier to test for more conditions, and each 
state has its own ways of determining which conditions to test for. 57 
In addition, only the District of Columbia requires parental informed 
consent, while not one of the fifty states does. 58 Only a few states 
require explicit consent from the infant's parents for screening the 
infant's blood. 59 Alternatively, some states have a "mixed-consent 
program" that allows parents to opt-out for "routine" testing based on 
religious beliefs, while certain "optional" tests are opt-in programs.60 
States also have their own statutes and regulations regarding what 
is done with the infant's blood sample after the screening is 
complete.61 In many cases, the samples are stored indefinitely. 62 
Only a few states have regulations requiring consent in order to use 
the samples in future research.63 
IV. THE CURRENT AND FUTURE LANDSCAPE OF NEWBORN 
SCREENING PROGRAMS CREATE PRIVACY PROBLEMS 
FOR THE PARENT AND INFANT 
Current legislation, procedures, and technology related to newborn 
screenings create both positive and negative implications that can 
affect the infant, the parents of the infant, and public health. 64 This 
section will first discuss some positive aspects of newborn 
screenings. 65 Next, it will discuss some current problems associated 
with newborn screening programs as well as future issues that may 
arise. 66 
57. See Davis, supra note 6, at 42; Schweers, supra note 6, at 879. The determination is 
further complicated by the fact that there are usually a number of different advocacy 
groups which campaign to have certain conditions added. See id. 
58. Timmermans, supra note 10. "Most states collect and test newborn samples after 
providing little, if any, educational primers to the parents. In fact, Michigan, 
Montana, Nebraska, and South Dakota do not currently provide any statutory grounds 
for refusal to participate." Schweers, supra note 6, at 880. See MICH. COMPo LAWS § 
333.5431 (2001); MONT. CODE ANN. §§ 50-19-201 to -211 (2013); NEB. REv. STAT. 
§§ 71-519 to -524 (2009); S.D. CODIFIED LAWS §§ 34-24-17 to -25 (2011). 
59. See Schweers, supra note 6, at 880. These programs are considered "opt-in." Id. 
60. Id. 880-81. 
61. See Cohen, supra note I. 
62. Id. Some states allow parents to request that their infant's DNA sample be destroyed. 
Id. 
63. See Davis, supra note 6, at 47-48. For example, in Michigan the BioTrust for Health 
was created which requires parental permission before stored samples are used in 
research. Id. 
64. Id. at 43-44. 
65. See infra Part IV.A. 
66. See infra Part IV.A-B. 
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There are many reasons why newborn screenings are a great idea 
for both the infant and the public at large. 67 Sometimes medical 
conditions cannot be seen through a traditional physical exam. 68 
Newborn screenings allow doctors to provide better care to the infant 
and can prevent serious problems, such as brain and organ damage as 
well as death. 69 In many cases, if it is determined that an infant has 
the genetic markers of a disease, then the doctor can prescribe a 
course of treatment or refer the parents to an appropriate specialist 
and prevent the infant from contracting that disease.7o If more infants 
are tested and subsequently treated for these diseases, the better the 
health of the public at large. 
A. Improper Selection D/Conditions To Be Tested For In A Newborn 
1. Problems Raised by Adult-Onset And Nontreatable Disorders 
While there are certainly positive aspects to newborn screening 
programs as they are structured today, there are many negative 
aspects as well.71 Ellen Wright Clayton, M.D., J.D., Professor of 
Genetics and Health Policy at Vanderbilt University, states that it is 
not a good idea to test newborns for adult-onset disorders and that 
informed consent should be required to screen for untreatable 
disorders. 72 Clayton further questions "why this screening should be 
done 1) by the state and 2) in the newborn period."73 First, she argues 
that clinicians should be the ones to speak with parents about the 
positives and negatives involved in newborn screening, rather than 
67. Newborn Screening, CTR. FOR DISEASE CONTROL & PREVENTION, 
http://www.cdc.gov/newbornscreeningl (last viewed June 27,2014). 
68. Pediatric Genetics: Newborn Screening, CTR. FOR DISEASE CONTROL AND 
PREVENTION, http://www.cdc.gov/ncbdddlpediatricgenetics/newborn ___ screening.html 
(last updated May l3, 20l3). 
69. Id. 
70. Id. For example, a doctor can prescribe a treatment plan for an infant with 
hypothyroidism, which is detected through newborn screening, to avoid the slowed 
growth and brain damage associated with hypothyroidism. Id. 
71. See, e.g., Bleicher, supra note 31 (stating that parents of an infant diagnosed with 
latent conditions tend to fret, pursue risky tests, and avoid routine treatment). An 
additional problem, which will not be addressed, is that in some states courts have 
held that parents either do not have the right to know the results of their infant's 
screening, or the laboratory is not required to notify the parents of the results. See In 
re Carter, 653 S.E.2d 860,866 (Ga. Ct. App. 2007); Hanshaw v. River Valley Health 
Sys., 789 N.E.2d 680, 687 (Ohio Ct. App. 2003). 
72. Ellen Wright Clayton, Ten Fingers, Ten Toes: Newborn Screening for Untreatable 
Disorders, 19 HEALTH MATRIX 199, 202---{)3 (2009). 
73. !d. 
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state officials.74 If state-run programs are tasked with obtaining 
parental consent, then it would "require a huge sea change since the 
vast majority of these programs have never sought parental 
permission."75 Second, Clayton argues that public and private 
clinicians continue to screen children for growth and development as 
well as other health problems as those children age. 76 She argues for 
a staged approach to testing for disorders, where different disorders 
are tested for at different times in a child's life. 77 
While testing newborns for adult-onset and nontreatable disorders 
create the problems described by Clayton, that should not mean that 
screening for such disorders at birth should be eliminated. 78 The real 
problem is not that these diseases are untreatable or don't manifest 
until the child is older, but rather that parents are not educated 
regarding their child's screening and are not given the chance to 
make an informed decision.79 Therefore, a tiered approach, which 
would create an isolated tier dedicated solely to testing for adult-
onset and nontreatable disorders and which requires parental 
informed consent, would be appropriate. 
Under many circumstances, clinicians are the best choice to 
educate parents before the child is born as well as during the child's 
developing years. 80 However, many parents either do not have access 
to consistent medical care for their child or choose not to seek out 
medical care.81 In such cases, a state program may be a more 
appropriate choice to educate parents who do not have regular access 
to a clinician's expertise.82 
2. Lack Of Consensus As To Which Conditions To Test For 
A glaring problem with current screening programs in the United 
States is that there is no consensus as to how many diseases an infant 
should be tested for. 83 In order to rectify this situation, in the 1990s 
the Health Resources and Services Administration commissioned a 
74. ld. at 202. 
75. ld. 
76. ld. at 201. 
77. See id. at 202. 
78. See, e.g., Schweers, supra note 6, at 875. 
79. See id. at 902. 
80. Clayton, supra note 72, at 201-202. 
81. The Med. Child Support Working Group's Report, 21 Million Children's Health: Our 
Shared Responsibility, PROMOTING RESPONSmLE FATIffiRHOOD, 
http://fatherhood.hhs.gov/medsupportOO/chapl.htm(lastupdated Nov. 27,2000). 
82. See Clayton, supra note 72, at 201-02. 
83. Bleicher, supra note 31. 
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researcher to review the scientific literature and determine which 
tests would benefit newborns.84 The report submitted recommended 
that all states screen for twenty-nine conditions and avoid screening 
for certain other conditions.85 However, this did not stop some states 
from testing for additional disorders, even though the report advised 
against it.86 
The additional conditions those states tested for are not always 
those that doctors can accurately predict or treat. 87 For example, New 
York has been testing infants for Krabbe disease since 2006. 88 
However, researchers do not currently understand Krabbe well 
enough to know when, or even if, the infant will develop symptoms 
(and, consequently, treatment is ineffective and inaccurate).89 As a 
result, parents "do not know what to do with the information they 
receive from doctors," and many "begin to worry."90 
Forcing parents (and infants) to participate in such a public health 
program is unfair.91 Given the expansion of genetic testing 
technology, and as genome-sequencing technologies become less 
expensive, there is the potential to test for hundreds of conditions 
which researchers and doctors do not understand. 92 It would seem 
unfair to force parents to submit their children to such a program 
when adults themselves can voluntarily decide not to participate in 
such a program on their own.93 While it is exciting to have the 
capability to test for so many things, "[ w]e shouldn't just add these 
things because we can. "94 Instead, legislation should attempt to 
create some uniformity by initially limiting states to testing only for 
84. Id.; Recommended Uniform Screening Panel, HEALTH RESOURCES AND SERVS. 
ADMIN., http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/ 
recommendedpanell (last updated Apr. 2013) (recommending that thirty-one core 
conditions be uniformly tested). 
85. Bleicher, supra note 31. It was found that some tests did not cause enough good to 




89. See id. 
90. Id. 
91. Id. However, it is true that testing for untreatable disorders can avoid delays in 
diagnosis, "providing parents with information about their children's health, allowing 
the earlier initiation of interventions, learning more about the natural history of these 
disorders, providing reproductive information to the family, and creating more 
opportunities to support these families." Clayton, supra note 72, at 201. 
92. Bleicher, supra note 31. 
93. See id. 
94. Jd. (quoting Jeff Botkin, a medical ethicist at the University of Utah School of 
Medicine). 
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certain recommended conditions.95 For any additional conditions to 
be added to the screening process those conditions should be put 
through rigorous tests to detennine the category that the condition 
belongs in.96 For example, a disorder might satisfy the same criteria 
as those disorders which are unifonnly tested. 97 Alternatively, 
disorders may fall under a separate category of conditions for which 
testing is not as reliable and/or treatment is not as successfu1.98 This 
categorization makes sure that conditions are not being tested for just 
because we can test for them.99 Rather, parents can become educated 
regarding the different categories and can make an infonned decision 
as to whether they consent to having their child tested for those 
disorders. 100 
B. A Lack Of Informed Consent Places The Burden On Parents 
Another negative aspect of current newborn screening programs 
has to do with inadequate parental infonned consent. 101 Currently, 
infonned consent to participate in a newborn screening program is 
only required in the District of Columbia and not in any other state. 102 
In many states, even though the parents are allowed to refuse, this 
right is meaningless, because parents are frequently not told about the 
test before the sample is taken. 103 
. Dena Davis,104 in her article Opportunistic Testing: The Death of 
Informed Consent?, focuses attention on the problems associated 
with a lack of infonned consent in newborn screening programs. lOS 
95. See Recommended Uniform Screening Panel, supra note 84; Schweers, supra note 6, 
at 903. 
96. See AM. ACAD. FAMILY PHYSICIANS, ISSUE BRIEF: NEWBORN SCREENING, (January 
2006), http://www.aafp.orgldarnl AAFP/documents/advocacy/workforce/scope/ES-
NewbornScreening-0106.pdf (recommending possible testing procedures for states 
including: (1) "that their states give consideration to mandatory newborn screening for 
those [diseases] for which the evidence is most rigorously supportive"; (2) "that 
families be appropriately informed for consent"; and (3) that "[fJamily physicians and 
their office staffs should prepare to educate families concerning newborn screening, 
and to respond to questions from families concerning positive tests"). 
97. See Schweers, supra note 6, at 903. 
98. See id. 
99. See id. 
100. See id. 
101. See Timmermans, supra note 10. 
102. Id. 
103. Davis, supra note 6, at 42. 
104. Davis is the Presidential Endowed Chair in Health, Humanities/Social Sciences at 
Lehigh University. Id. at 35. 
105. Id. 
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First, Davis explains that there is a debate regarding how to choose 
which conditions are added to existing newborn screening tests. 106 
Underlying this debate is the concept of informed consent (or lack 
thereof)107 and that "[a] test given without parental consent can only 
ethically be defended on the grounds of potential benefit to children, 
backed up by strong evidence."108 Davis warns that while some 
conditions may pass this test, others may not. 109 
Additionally, Davis discusses how false positives can be a major 
problem, especially if no informed consent is required. IIO In order to 
avoid these problems, Davis suggests that parents need to become 
more involved in newborn screening programs. III To do this, parents 
need to receive as much information as possible during the prenatal 
period in order for them to acclimate to the information and ask 
questions. 112 
Davis is absolutely correct, and the idea that parents must be 
involved and educated regarding newborn screenings is the exact 
reason why the burden for protecting the infant's privacy must be 
shifted away from the parents. 1i3 For example, society automatically 
assumes that patients should be informed about the procedure, risks 
involved, and prognosis relating to surgery and other procedures 
performed by physicians. 114 Society needs to begin thinking the same 
way regarding newborn screening programs in order to properly 
protect the parent's and, more importantly, the infant's privacy as 
screening technologies become more advanced. 
Further exacerbating the problem associated with this lack of 
proper informed consent, hospitals use a tactic known as 
106. Jd. at 42. 
107. Jd. The author writes that "the ease with which new screens can be added threatens 
parental rights to be aware of and consent to the medical tests conducted on their 
children .... " Jd. at 48. 
108. Jd. at 42-43. 
109. Jd. at 43. PKU probably passes this test, but "[s]creening for cystic fibrosis, for 
example, has been controversial because not everyone agrees that there is a medical 
advantage to early, presymptomatic diagnosis. However, studies show that early 
diagnosis of cystic fibrosis prevents malnutrition and improves children's growth and 
cognitive function." Jd. at 43. In addition, we need to question what counts as a 
"benefit." See id. 
110. Jd. at 44. 
111. Jd. at 45. 
112. Jd. The author suggests several ways of doing this, including information from the 
internet, brochures, etc. Jd. at 45-46. 
113. See infra Part V. 
114. See Owen A. Anderson & I Mike 1. Wearne, Jnformed Consent for Elective Surgery-
What is Best Practice?, 100 J. OF ROYAL SOC'y OF MED. 97, 97-99 (2007), available 
at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 1791 005/. 
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opportumstIc testing. 115 Put simply, "Opportunistic testing or 
screening is medical testing that makes use of an 'opportunity' 
engendered by some other test ... to which the patient is accustomed 
or has already given consent."116 In a situation in which a blood 
sample is used, opportunistic testing means that the "sample is drawn 
for an established purpose and then one or more extra tests are 
added" to that initial test. 117 This creates obvious problems, because 
parents may give consent to one test, but without their knowledge be 
subjected to additional tests.IIB How can this be acceptable, when it 
would not be acceptable to obtain consent for a particular heart 
procedure, for example, and then allow the surgeon to perform an 
additional procedure for which proper, explicit consent was not 
obtained? 
Newborn screening program advocates have also tried to add more 
conditions to the testing list as well as incorporate genetic sequencing 
into the program. 119 The National Institute of Child Health and 
Human Development and the National Human Genome Research 
Institute are currently funding research proposals to integrate gene 
sequencing technologies into newborn screening programs which 
may allow us to provide every newborn with a full genetic printout at 
birth. 120 As noted above, however, sometimes these tests can yield 
false positives or can test for diseases that are untreatable. 121 A lack 
of informed consent means that parents will be notified that their 
child has a condition they did not know was even tested for during 
the initial screening. 122 This can devastate parents and cause them to 
worry. 123 
Furthermore, if parents do not know exactly what is being done to 
their child, the information being collected (in this case the infant's 
DNA) can be used for nefarious purposes. 124 These purposes can 
115. See Davis, supra note 6, at 36. 
116. ld. The tenn "implies 'piggybacking' one intervention onto another and thus 
exploiting an opportunity." Jd. 
117. Jd. 
liS. ld. 





124. See, e.g., Becca Aaronson, Lawsuit Alleges DSHS Sold Baby DNA Samples, TEx. 
TRIBUNE (Dec. S, 2010), http://www.texastribune.org/2010/12/0S/lawsuit-alleges-
dshs-sold-baby-dna-samplesl (indicating that the Texas Department of State Health 
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include unlawfully distributing infant blood samples or glvmg 
samples to outside researchers without consent. 125 
Rachel L. Schweers points out correctly that since each state has its 
own rules, there is no true uniformity regarding these programs, and 
as a result privacy rights are eroded and in some cases violated. 126 
Schweers suggests that there should be a model newborn screening 
statute among all programs throughout the country.127 This model 
should require explicit informed consent from the parents. 128 In 
addition, discussions with healthcare providers should include (1) the 
conditions tested, (2) "the disclosure of the results," (3) "the retention 
time or ... destruction of the sample," and (4) "the permissible 
research uses of the sample."129 Schweers suggests that there should 
be a tiered system regarding which conditions are tested for and what 
amount of consent is required. 130 Schweers writes that the only 
standard conditions which should be tested for are those that are 
"known to benefit from diagnosis and treatment at an early stage in 
life."131 With regard to permissible research uses, Schweers suggests 
"parents should be given the option of electing sample retention for 
no longer than eighteen years .... "132 
C. Genome Sequencing As The Future of Newborn Screenings 
In the field of genomics, the goal of technology moving forward is 
to have the ability to sequence an entire genome quickly, accurately, 
and for low cost. 133 Cost is one of the most significant barriers to 
creating widely available sequencing opportunities, but next-
generation technologies indicate that low-cost genome sequencing is 
on the way. 134 Further, genome sequencing has tremendous value: 
Services sold and distributed infant blood samples to outside laboratories without 
parental consent). 
125. See id.; Cohen, supra note 1. 
126. Schweers, supra note 6, at 879. 
127. Jd. at 900. 
128. Jd. 900-01. 
129. Jd. at 900-901. 
130. See id. at 903. 
131. Jd. 
132. Jd. at 904. 
133. Mark A. Rothstein, Column, Currents in Contemporary Bioethics: The Case Against 
Precipitous, Population-Wide, Whole-Genome Sequencing, 40 J.L. MED. & ETHICS 
682, 682 (2012). Mr. Rothstein "is the Herbert F. Boehl Chair of Law and Medicine 
and Director, Institute for Bioethics, Health Policy and Law, University of Louisville 
School of Medicine." Jd. 
134. See id. 
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[I]n elucidating the genetic etiology of rare disorders, in 
identifying atypical variants in common diseases, in 
determining pharmacogenomically appropriate drugs and 
dosages, in performing tumor genome sequencing, and in 
aiding other clinical applications for the diagnosis and 
treatment of individuals who are symptomatic or whose 
family health history places them at substantial risk. 135 
119 
Moreover, the development, promotion, and use of new sequencing 
technologies will not slow down as a result of societal opinions, and 
as soon as it is technically and financially feasible, population-wide 
genome sequencing will occur. 136 
Mark Rothstein critically evaluates population-wide, whole-
genome sequencing and concludes that the costs associated with such 
sequencing outweigh any potential benefits.137 Rothstein's concerns 
with population-wide, whole-genome sequencing are numerous (only 
a few of which are discussed here). 138 
First, "[i]t is not clear how sequence data [is] interpreted." 139 
Currently, no standardized software exists for performing 
sequencing, and it is not clear whether the FDA would have to get 
involved in such a process. 140 Second, Rothstein questions whether 
health care providers have the expertise and time to translate the 
genome sequence data and develop prevention and treatment plans 
for each patient. 141 
Rothstein further argues that informed consent should be conducted 
in the clinical setting, but the sheer magnitude of information 
obtained from sequencing the entire genome would create numerous 
135. ld. (emphasis in original) (footnotes omitted). 
136. ld. 
137. ld. 
138. ld. at 683-87. 
139. ld. at 684. 
140. See id. 
141. ld. at 684-85. 
Physicians who routinely deal with genetics include obstetricians, 
pediatricians, neurologists, and oncologists. Primary care 
physicians generally do not have significant training or experience 
in traditional clinical genetics, let alone the increasingly arcane 
world of molecular genetics and genomics. Furthermore, third-
party payers may not pay for genetic counseling, and in all but 5 
states genetic counselors cannot bill for their services independent 
of an affiliated clinical geneticist. 
ld. at 685. 
120 UNIVERSITY OF BALTIMORE LAW REVIEW Vol. 44 
problems in obtaining proper informed consent. 142 Rothstein finds 
that this flaw is almost impossible to overcome, unless there is a 
major revolution in the healthcare field. 143 
Finally, Rothstein argues that there is an absence of health privacy 
and discrimination protections. l44 Mainly, Rothstein points to the 
Health Insurance Portability and Accountability Act (HIP AA) and the 
Genetic Information Nondiscrimination Act (GINA) as flawed 
legislation whose flaws are compounded when a large volume of 
information is generated, as is the case with whole-genome 
sequencing. 145 Without solutions for the issues with this legislation, a 
patient's privacy and nondiscrimination rights are in jeopardy. 146 
As discussed above, a tiered approach is an appropriate way to 
solve some of the above-mentioned negative aspects of newborn 
screening programs. 147 This is especially true when we consider that 
the future of genetic testing-who Ie-genome sequencing-is 
becoming less expensive and more accurate. 148 As sequencing begins 
to enter the newborn screening arena, we must be cognizant of the 
risks which surface if there is a severe lack of uniformity and 
education among parents. 149 A tiered system which creates a separate 
tier for genome sequencing would help society to adjust and face the 
reality that genome sequencing presents. 150 
142. Id. "[A]s a result of sequencing, an average person will have about 100 genetic risks 
that will need to be discussed. If each risk were covered in 3 minutes, it would take 5 
hours of patient contact to explain the risks." Jd. 
143. Id. 
144. Id. at 686-87. 
145. Id. at 686. 
146. See id. 
147. See supra Part IV. 
148. See Bleicher, supra note 31; Pollack, supra note 33. 
149. Audrey Tluczek et aI., Newborn Screening: An Appeal for Improved Parent 
Education, 23 J. PERINATAL & NEONATAL NURSING 326, 333 (2009), available at 
http://www.ncbi.nlm.nih.gov/pmc/articies/PMC2947955/. 
150. See Schweers, supra note 6, at 903-04; Rothstein, supra note 133, at 682-83. 
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V. AS A SOCIETY WE NEED TO CHANGE THE WAY WE 
LOOK AT GENETIC INFORMATION AND SHIFT THE 
BURDEN OF PRIVACY TO LABORATORIES AND 
HEALTH CARE PROVIDERS 
A. Society Needs To Fundamentally Change The Way We Look At 
Genetic Information 
121 
The United States has an outdated view regarding the privacy of 
newborn screenings. 151 When newborn screening programs were first 
implemented and related legislation was created, genetic testing 
technology was not as advanced as it is todayI52 (we could only test 
for a few diseases and not much else). 153 What has changed since 
then is that we have now unlocked the human genome and have 
begun reading and analyzing the sequence to learn as much as we can 
about human DNA. 154 What this means is that we can now not only 
determine an individual's predisposition for a multitude of diseases, 
but we can identify personality traits and physical traits as well. 155 It 
is true that we have not progressed too far into deciphering 
personality and physical traits, but that ability is not so far in the 
distant future. 156 The power that this technology holds creates many 
problems that our old way of thinking is woefully incapable of 
solving. 157 
Society needs to change its thinking regarding genetic information. 
Genetic information is the most personal information a person can 
have. 15s An individual's genetic code can be considered a "coded 
future diary" 159 and "the ultimate answer to the commandment 
151. See Jonathan Hsu, Note, Genetic Testing: Balancing Preventative Medicine with 
Privacy and Nondiscrimination, 6 J.L. & POL'y FOR INFO. SOC'y 557,558-59 (2011). 
152. See Diane B. Paul, Promoting Safe and Effective Genetic Testing in the United States. 
App. 5: The History of Newborn Phenylketonuria Screening in the U.S., LAW, 
SCIENCE & PUBLIC HEALTH PROGRAM SITE OF LA. STATE UNIV. (Sept. 1997), 
http://biotech.law.lsu.eduJresearchifedltfgt/appendix5.htm; All About the Human 
Genome Project (HGP), supra note 32. 
153. See Paul, supra note 152. 




155. See supra note 9 and accompanying text. 
156. See Davis, supra note 6, at 41-42. 
157. See supra Part IV. 
158. See All About the Human Genome Project (HGP), supra note 32. 
159. Hsu, supra note 151, at 573. 
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'[k ]now thyself. "'160 It can be argued that it is even more personal 
and private than an individual's social security number. 161 Such 
personal information must be protected to the great~st extent 
possible, and while new parents have neither the appropriate 
information nor the ability to refuse newborn screenings, the burden 
is on them to affirmatively protect their and their child's privacy. 162 
This Comment proposes that we implement a two-pronged 
approach to solve this issue. 163 First, legislation should require 
parental informed consent in order for the infant to participate in the 
newborn screening program. 164 This would mean a new generation of 
parents would be better informed about what genetic information is, 
what current (and potential future) technology exists, and the 
positives and negatives of genetic testing. 165 Second, legislation 
should place the onus on healthcare providers, corporations, research 
institutions, and other entities not to violate the parents' or infant's 
privacy rights. 166 This would effectively shift the burden away from 
the parent and would not put the infant's genetic information at as 
great a risk. 167 
B. Restructuring Current Newborn Screening Programs 
One major issue to consider regarding newborn screening programs 
is which conditions to test for. 168 Obviously, there are certain 
diseases that are treatable if detected early,169 and testing and treating 
those conditions can make a previously difficult or shortened life 
more normal. 170 It is less clear whether adult onset or untreatable 
disorders should be included as well. 171 Clayton suggests that 
clinicians should be the only ones who should obtain informed 
160. Id. (quoting JERRY E. BISHOP & MICHAEL WALDHOLZ, GENOME: THE STORY OF THE 
MOST ASTONISHING SCIENTIFIC ADVENTURE OF OUR TIME 218 (Touchstone Books 
1991)). 
161. Genetic infonnation should be held to a higher standard than a social security number. 
See The Privacy Act and the Freedom of Information Act, SOCIAL SEC. ADMIN., 
http://www.ssa.gov/privacyact.htm (last visited Nov. 17,2014). 
162. See Davis, supra note 6, at 42. 
163. See supra Part IV.B-C. 
164. See supra Part IV.B. 
165. See supra Part IV.B. 
166. See supra Part IV.C. 
167. See supra Part IV.B. 
168. See Bleicher, supra note 31. 
169. See Recommended Uniform Screening Panel, supra note 84. 
170. See Davis, supra note 6, at 42-43. 
171. Clayton, supra note 72, at 20 I . 
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consent from parents and questions whether nontreatable disorders 
should be included in the testing panel to begin with. 172 
Requiring that consent only be obtained by clinicians is important 
in proper education of the parents. 173 Clinicians typically have close 
relationships with their patients and patients have a certain level of 
respect for their clinicians. 174 As a result, a better dialogue would 
occur if parents are informed of all aspects of the screening process 
and the clinician obtains consent. 175 
However, just because a condition is nontreatable or will not show 
itself until the infant is an adult should not mean that it is appropriate 
to deny testing for those conditions. 176 Clayton argues that what 
would be more appropriate is to test for such conditions on a 
continuous basis as the child gets older. 177 Part of the purpose of 
informed consent is to educate parents and allow them to make an 
informed decision. 178 As such, some parents may want to test the 
child for these conditions all at once, and it should be their choice 
whether or not to do SO.179 
As stated above, the foundation for good policy regarding newborn 
screening programs absolutely needs to start with parental informed 
consent. 180 Davis's suggestion that parents should have access to a 
lot of information during the prenatal period is a good one. 181 
However, it would not work well enough. Informed consent may 
solve the problem that a false positive presents,182 but it does not 
solve the problem of researchers and policy-makers wanting to 
continue to add conditions to be tested for through a screening 
program. 183 Therefore, in order for a new condition to be added to 
the panel, it would have to pass several tests, including, but not 
limited to, whether it is treatable, the severity of the effects of the 
disorder, the reliability of testing, and the ease of testing. 
In addition, from a theoretical standpoint, the model guidelines that 
Schweers proposes are a good start toward adequate privacy 
172. ld. at 201-{)2. 
173. See id. 
174. See id. 
175. See id. 
176. See id. at 203. 
177. See id. at 202-{)3. 
178. See Davis, supra note 6, at 45-46. 
179. Clayton, supra note 72, at 203. 
180. See id. at 202. 
181. Davis, supra note 6, at 45-46. 
182. See id. 
183. See id. at 42. 
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protection. 184 Many of the problems addressed by Schweers would 
be solved if states unifonnly implemented her model guidelines. A 
tiered approach which requires infonned consent at every level is a 
clever and potentially effective way of assuring that parents are not 
bombarded with too much infonnation all at once. 185 Each tier would 
consist of different tests and would require infonned consent. The 
first level would consist of a panel of diseases which are unifonnly 
tested by all programs. 186 The second level should consist of tests 
which are less reliable and do not have as great of a success rate after 
treatment. The third level should consist of nontreatable disorders 
and adult-onset disorders. Finally, the fourth level should consist of 
whole-genome sequencing and related testing. 
Contrary to what Rothstein argues, it is possible to overcome the 
costs of incorporating whole-genome sequencing into newborn 
screening programs. 187 Rothstein argues that clinicians do not have 
the time or expertise to translate the genome sequence data and 
develop prevention and treatment plans for each patient. 188 However, 
while it is difficult for clinicians to do this now, as technology 
advances, it will get easier.189 
C. Fixing Issues Presented by HIP AA 's Framework 
HIP AA is a statute that sets out rules and regulations, which 
ultimately create an affinnative duty on the part of the healthcare 
provider not to disseminate or in any other way use an individual's 
personal health infonnation without the explicit consent of the 
individual. 190 If an entity falls under the scope of HIP AA, "it may not 
disclose 'protected health infonnation' without the patient's 
authorization . . . ."191 To protect health infonnation "[such 
infonnation] must be individually identifiable and maintained by a 
covered [entity]."192 The U.S. Department of Health and Human 
184. See supra text accompanying notes 128-34. 
185. See Schweers, supra note 6, at 906. 
186. The panel proposed by the Health Resources and Services Administration might be a 
reasonable option. See Recommended Uniform Screening Panel, supra note 84. 
187. See Pollack, supra note 33. 
188. Rothstein, supra note 133, at 685. 
189. See DNA Sequencing, supra note 34. 
190. See Health Information Privacy, supra note 15. 
191. Hsu, supra note 151, at 578. 
192. Does the HIPAA Privacy Rule Protect Genetic Information?, U.S. DEP'T OF HEALTH 
& HUMAN SERVS., 
http://www .hhs.gov/ocr/privacylhipaalfaqlprotected _health _ informationl354 .html 
(last updated March 14,2006); 45 C.F.R §§ 160.103,164.501 (2013). This defmition 
might not apply to un-identified samples. See id. 
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Services considers genetic infonnation to be included In this 
definition. 193 However, HIP AA does not apply to all genetic 
screenings, because the "default guardian[ s] of personal genetic 
infonnation" are not "covered entities" under HIP AA.194 
Furthennore, HIP AA "does little to limit secondary uses of health 
infonnation .... "195 
In addition to legislation that would create unifonnity and require 
infonned consent,196 legislation should include requirements similar 
to HIP AA but tailored specifically toward an expanded definition of 
the tenn "genetic infonnation" and which apply to a wider range of 
entities. First, in such legislation, the tenn "genetic infonnation" 
should be defined to include any infonnation about a genetic test, 
including analyses of "human DNA, RNA, chromosomes, proteins, 
or metabolites," as long as the analysis "detects genotypes, mutations, 
or chromosomal changes."197 Further, "genetic infonnation" should 
include any infonnation relating to an individual's genetic counseling 
or genetic education. 198 Finally, "genetic infonnation" should include 
any method of obtaining the sample, such as via blood, skin, or 
hair. 199 
Second, legislation would seek to encompass entities which are not 
included in HIP AA. 200 The tenn "covered entities" would be defined 
as any entity that obtains the genetic infonnation of an individual 
through a newborn screening program or voluntary genetic test. 201 
These entities would consist of covered entities, as described in 
HIP AA, as well as corporations, research institutions, public and 
193. Health Information Privacy, supra note 15. But it is not specified what "genetic 
infonnation" includes. See 45 C.F.R § 160.103. 
194. Privacy & Ownership of an Individual's Personal Genetic Information, GENOMICS 
LAW REpORT (Oct. 29, 2009), 
http://www.genomicslawreport.comlindex.php/2009/10/29/privacy-ownership-of-an-
individuals-personal-genetic-infonnationl. Corporations such as direct-to-consumer 
genetic testing companies are not considered "covered entities." Id. "[HIP AA] only 
applies to the following three classes of covered entities involved in health claims: 
health care providers, health plans, and health clearinghouses." Rothstein, supra note 
133, at 686. 
195. Rothstein, supra note 133, at 686. 
196. See supra Part IV.B. 
197. FAQs on the Genetic Information Nondiscrimination Act, U.S. DEP'T OF LABOR, 
http://www.dol.gov/ebsa/faqs/faq-GINA.html(last visited Nov. 17,2014). 
198. Id. 
199. See id. 
200. Rothstein, supra note 133, at 686. 
201. See Ellen Wright Clayton, Screening and Treatment of Newborns, 29 Hous. L. REv. 
85, 144-45 (1992); supra Part 1. 
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private universities, and testing laboratories.202 Increasing the scope 
of covered entities would assure that an individual's privacy rights 
are not in jeopardy simply because an entity does not fit into the 
statute's definition.203 Overall, if the above definitions are 
incorporated into legislation, the main issues presented by HIP AA are 
eliminated and the burden on protecting the infant's privacy is shifted 
away from parents and onto the entities conducting the analyses. 
VI. CONCLUSION 
While there are many obvious pOSItIves to newborn genetic 
screenings, we must realize that some problems with current 
programs create privacy issues for the infant. 204 Current and future 
genetic testing technology holds tremendous power which can affect 
the lives of parents and their children.205 In order to fully protect an 
infant's privacy rights relating to their genetic information, society 
must change from its old way of thinking about what genetic 
information is.206 To do this, this Comment proposes that not only 
should we require parents to be informed of newborn screening 
technologies, processes, and policies, but a statute should exist which 
is similar in effect to HIP AA that will create an affirmative duty of 
confidentiality on any entity or person who becomes associated with 
the infant's genetic information.207 
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